The Institute for Healthier Living Abu Dhabi (IHLAD), the world’s first government-licensed healthy longevity medicine center, has partnered with CoreX to establish the UAE’s first bio-intelligence engine based on a specific population.
The initiative harnesses artificial intelligence (AI) and organ-on-chip biological models, which simulate human organs and tissues, to learn directly from human biology. This approach will deliver population-specific insights that enhance drug safety and advance precision medicine.
The collaboration between IHLAD, which helps people live healthier lives through precision diagnostics, lifestyle medicine and evidence-based therapeutics, and CoreX, an AI-driven biotech company established in Abu Dhabi, makes the UAE the first country in the world to deploy a bio-intelligence engine, a system using AI to process biological data, built on the human biology of its indigenous population rather than foreign datasets.
The ability to deliver UAE-relevant insights supports safer, more informed decision-making about medicine use by more reliably predicting how patients will respond to medications, helping to reduce avoidable reactions, identifying risks earlier and guiding a more personalized treatment plan.
It also creates a pathway for more representative drug development by enabling pharmaceutical companies to evaluate medicines against biology that reflects the UAE’s real genetic, metabolic and clinical characteristics.
The bio-intelligence engine will enhance health outcomes in the UAE, strengthen national health security, and showcase Abu Dhabi as a hub for global pharmaceutical and research partnerships. As IHLAD becomes CoreX’s institutional anchor, the platform will attract pharma, biotech, and life-science companies seeking human-relevant models for safe, efficient, and locally reflective drug discovery, supporting the UAE’s vision for a secure, future-ready biomedical ecosystem.
Built as a phased, multimodal AI platform, the engine integrates patient-specific organoid and organ-on-chip models, biological and functional Bio-AI data, and population-specific datasets, including Emirati and regional data. This predictive system improves drug-response modelling, enables precision medicine at scale, and creates a protected national biological-intelligence resource.
Nicole Sirotin CEO-IHLAD
“Our partnership with CoreX to build the UAE’s first national bio-intelligence engine is about bringing advanced AI together with patient-specific organ-on-chip models for more precise prediction for the Emirati population and the people we serve. We will now have a platform to study organ-specific longevity models with the goal of extending healthy years of life.”
Dr Isaac Bentwich, Founder and Global CEO of CoreX, said that, “CoreX uniquely integrates AI and organ-on-chip living biology to revolutionize medicine discovery, optimization and validation. This partnership with IHLAD lets us build a platform for the UAE, grounded in scientific rigor, population relevance and predictive insight that will serve the region for generations to come.”
IHLAD and CoreX are advancing Abu Dhabi’s leadership in longevity, precision health, and next-generation medical innovation. The partnership supports the global shift toward human-centric healthcare and lays the foundation for a predictive, future-ready health ecosystem in the UAE.
